Literature DB >> 6248544

Two different intrachain cAMP binding sites of cAMP-dependent protein kinases.

S R Rannels, J D Corbin.   

Abstract

The regulatory subunits of both isozymes of cAMP-dependent protein kinase bind 2 mol of cAMP/mol of monomer. cAMP dissociation studies indicate similar cAMP binding behavior for each isozyme. Each has two different intrachain cAMP binding components present in approximately equal amounts and the rate of cAMP dissociation is 5- to 10-fold slower from one site (Site 1) than from the other (Site 2). Equilibrium [3H]cAMP binding is inhibited by several competing cyclic nucleotides. Following equilibrium binding using saturating [3H]cAMP in the presence of competing nucleotide, the pattern of release of [3H]cAMP, monitored in the presence of an excess of nonradioactive cAMP, suggests site-specific selectivity of some of the cyclic nucleotides. As compared with cAMP, cIMP prefers Site 2 for both regulatory subunits, whereas N6, O2-dibutyryl-cAMP shows a similar preference only with isozyme II regulatory subunit. 8-Bromo-cAMP, 8-bromo-cGMP, and 8-azido-cAMP prefer Site 1 of both proteins. The results indicate that for each isozyme the two intrachain binding sites have different analogue specificities and cAMP dissociation rates. Site 1 or Site 2 of one isozyme has a similar but not identical cyclic nucleotide specificity and cAMP dissociation rate to the corresponding site of the other isozyme.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6248544

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

1.  Resonant mirror biosensor analysis of type Ialpha cAMP-dependent protein kinase B domain--cyclic nucleotide interactions.

Authors:  W W Muhonen; J B Shabb
Journal:  Protein Sci       Date:  2000-12       Impact factor: 6.725

2.  Extracellular protein kinase A as a cancer biomarker: its expression by tumor cells and reversal by a myristate-lacking Calpha and RIIbeta subunit overexpression.

Authors:  Y S Cho; Y G Park; Y N Lee; M K Kim; S Bates; L Tan; Y S Cho-Chung
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

3.  cAMP analogs promote survival and neurite outgrowth in cultures of rat sympathetic and sensory neurons independently of nerve growth factor.

Authors:  R E Rydel; L A Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

4.  Characterization of cyclic GMP-binding sites of cyclic GMP-dependent protein kinase by rapid filtration assay.

Authors:  M Hirai; S Hashimoto; T Kuno; C Tanaka
Journal:  Biochem J       Date:  1988-10-15       Impact factor: 3.857

5.  Protein kinase a-dependent phosphorylation of serine 119 in the proto-oncogenic serine/arginine-rich splicing factor 1 modulates its activity as a splicing enhancer protein.

Authors:  Anne Kristin Aksaas; Sissel Eikvar; Göran Akusjärvi; Bjørn S Skålhegg; Anne Katrine Kvissel
Journal:  Genes Cancer       Date:  2011-08

6.  Fine-structure mapping of charge-shift mutations in regulatory subunit of type I cyclic AMP-dependent protein kinase.

Authors:  R A Steinberg
Journal:  Mol Cell Biol       Date:  1984-06       Impact factor: 4.272

7.  A constitutively active holoenzyme form of the cAMP-dependent protein kinase.

Authors:  Y H Wang; J D Scott; G S McKnight; E G Krebs
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

8.  Genetic characterization of a brain-specific form of the type I regulatory subunit of cAMP-dependent protein kinase.

Authors:  C H Clegg; G G Cadd; G S McKnight
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

9.  Isoleucine 368 is involved in low-affinity binding of N6-modified cAMP analogues to site B of the regulatory subunit of cAMP-dependent protein kinase I.

Authors:  I Huq; W R Dostmann; D Ogreid
Journal:  Biochem J       Date:  1996-05-15       Impact factor: 3.857

10.  Selective modulation of protein kinase isozymes by the site-selective analog 8-chloroadenosine 3',5'-cyclic monophosphate provides a biological means for control of human colon cancer cell growth.

Authors:  S Ally; G Tortora; T Clair; D Grieco; G Merlo; D Katsaros; D Ogreid; S O Døskeland; T Jahnsen; Y S Cho-Chung
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.